Alexander E. Perl

15.7k total citations · 3 hit papers
200 papers, 6.3k citations indexed

About

Alexander E. Perl is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Alexander E. Perl has authored 200 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Hematology, 86 papers in Genetics and 49 papers in Molecular Biology. Recurrent topics in Alexander E. Perl's work include Acute Myeloid Leukemia Research (148 papers), Chronic Myeloid Leukemia Treatments (95 papers) and Chronic Lymphocytic Leukemia Research (64 papers). Alexander E. Perl is often cited by papers focused on Acute Myeloid Leukemia Research (148 papers), Chronic Myeloid Leukemia Treatments (95 papers) and Chronic Lymphocytic Leukemia Research (64 papers). Alexander E. Perl collaborates with scholars based in United States, Germany and Italy. Alexander E. Perl's co-authors include Mark J. Levis, Martin Carroll, Ross L. Levine, Craig B. Thompson, Omar Abdel‐Wahab, Catherine C. Smith, Valeria R. Fantin, Joshua D. Rabinowitz, David R. Wise and Cyrus V. Hedvat and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Alexander E. Perl

192 papers receiving 6.2k citations

Hit Papers

The Common Feature of Leukemia-Associated IDH1 and IDH2 M... 2010 2026 2015 2020 2010 2012 2022 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
    2010 1.5k citations Alexander E. Perl, Martin Carroll et al. profile →
  2. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
    2012 542 citations Catherine C. Smith, Chen-Shan Chin et al. profile →
  3. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
    2022 123 citations Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexander E. Perl United States 37 3.9k 3.2k 1.6k 1.1k 942 200 6.3k
Ilene Galinsky United States 32 3.3k 0.8× 2.6k 0.8× 1.9k 1.2× 446 0.4× 969 1.0× 84 5.3k
Daniel A. Pollyea United States 44 6.0k 1.5× 4.6k 1.5× 1.6k 1.0× 1.1k 1.0× 1.4k 1.5× 211 8.4k
B. Douglas Smith United States 43 4.2k 1.1× 2.8k 0.9× 1.5k 1.0× 370 0.3× 1.3k 1.4× 171 6.3k
Jeffrey E. Lancet United States 48 5.3k 1.3× 3.5k 1.1× 2.1k 1.3× 399 0.4× 1.8k 1.9× 437 7.8k
Keith W. Pratz United States 33 4.2k 1.1× 2.5k 0.8× 1.4k 0.9× 271 0.2× 962 1.0× 128 5.2k
Raoul Tibes United States 34 1.4k 0.4× 3.6k 1.1× 771 0.5× 576 0.5× 1.5k 1.6× 144 5.3k
Shaoguang Li United States 29 2.3k 0.6× 1.6k 0.5× 1.4k 0.9× 301 0.3× 651 0.7× 104 3.9k
Olatoyosi Odenike United States 33 2.2k 0.5× 1.6k 0.5× 1.1k 0.7× 217 0.2× 723 0.8× 156 3.6k
Jonathan L. Kaufman United States 45 5.2k 1.3× 5.0k 1.6× 964 0.6× 615 0.5× 3.6k 3.8× 323 7.9k
Ivana Gojo United States 36 2.2k 0.5× 2.5k 0.8× 523 0.3× 260 0.2× 1.6k 1.7× 136 4.3k

Countries citing papers authored by Alexander E. Perl

Since Specialization
Citations

This map shows the geographic impact of Alexander E. Perl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander E. Perl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander E. Perl more than expected).

Fields of papers citing papers by Alexander E. Perl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander E. Perl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander E. Perl. The network helps show where Alexander E. Perl may publish in the future.

Co-authorship network of co-authors of Alexander E. Perl

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander E. Perl. A scholar is included among the top collaborators of Alexander E. Perl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander E. Perl. Alexander E. Perl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Levis, Mark J., Alexander E. Perl, Gary J. Schiller, et al.. (2024). A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood Advances. 8(10). 2527–2535. 9 indexed citations
3.
Brown, Fiona C., Richard W. Birkinshaw, Chong Chyn Chua, et al.. (2024). Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia. Blood Advances. 9(1). 127–131. 7 indexed citations
4.
Abaza, Yasmin, Eric S. Winer, Guru Subramanian Guru Murthy, et al.. (2024). Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers. American Journal of Hematology. 99(4). 606–614. 12 indexed citations
5.
Perl, Alexander E., Mark J. Levis, Andrew H. Wei, et al.. (2024). Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia. Blood. 144(Supplement 1). 2889–2889.
6.
Palmisiano, Neil, Grace R. Jeschke, Lindsay Wilde, et al.. (2023). A Phase I Trial of Sirolimus with “7&3” Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia. Cancers. 15(21). 5129–5129.
7.
Pratz, Keith W., Mohamad Cherry, Jessica K. Altman, et al.. (2023). Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal of Clinical Oncology. 41(26). 4236–4246. 27 indexed citations
8.
Caplan, Avrom S., Robert D. Schwab, Emily Baumrin, et al.. (2023). Vitamin C deficiency in patients with acute myeloid leukemia: a case series and review of the literature. Blood Advances. 7(19). 5780–5783. 3 indexed citations
9.
Daver, Naval, Alexander E. Perl, Joseph Maly, et al.. (2022). Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 40(35). 4048–4059. 123 indexed citations breakdown →
10.
Matthews, Andrew, Alexander E. Perl, Selina M. Luger, et al.. (2022). Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Advances. 6(13). 3997–4005. 53 indexed citations
11.
Loren, Alison W., Elizabeth O. Hexner, Mary Ellen Martin, et al.. (2022). Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Transplantation and Cellular Therapy. 29(2). 113–118. 2 indexed citations
12.
Perl, Alexander E., Naoko Hosono, Pau Montesinos, et al.. (2022). Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal. 12(5). 84–84. 27 indexed citations
13.
Hurtz, Christian, Gerald Wertheim, Joseph P. Loftus, et al.. (2020). Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. Journal of Clinical Investigation. 130(7). 3637–3653. 32 indexed citations
14.
Smith, Catherine C., Mark R. Litzow, Alexander E. Perl, et al.. (2020). Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical Pharmacokinetics. 59(10). 1273–1290. 50 indexed citations
15.
Schwartz, Gregory W., Yeqiao Zhou, Priya Velu, et al.. (2018). Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors. Clinical Cancer Research. 25(2). 573–583. 7 indexed citations
16.
Hou, Panpan, Chao Wu, Yuchen Wang, et al.. (2017). A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. Cancer Research. 77(16). 4402–4413. 68 indexed citations
17.
Smith, Catherine C., Amy L. Paguirigan, Grace R. Jeschke, et al.. (2017). Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 130(1). 48–58. 120 indexed citations
18.
Torres‐Martín, Miguel, Grace R. Jeschke, Alexander E. Perl, Martin Carroll, & María E. Figueroa. (2017). Differentiation Response to Quizartinib, a Potent 2nd Generation FLT3 Inhibitor, in Relapsed FLT3 -Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy. Blood. 130. 3922. 1 indexed citations
19.
20.
Tsai, Donald E., Selina M. Luger, Charalambos Andreadis, et al.. (2008). A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Clinical Cancer Research. 14(17). 5619–5625. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilene Galinsky Breakdown of academic impact, for papers by Daniel A. Pollyea Breakdown of academic impact, for papers by B. Douglas Smith Breakdown of academic impact, for papers by Jeffrey E. Lancet Breakdown of academic impact, for papers by Keith W. Pratz Breakdown of academic impact, for papers by Raoul Tibes Breakdown of academic impact, for papers by Shaoguang Li Breakdown of academic impact, for papers by Olatoyosi Odenike Breakdown of academic impact, for papers by Jonathan L. Kaufman Breakdown of academic impact, for papers by Ivana Gojo
Rankless by CCL
2026